 The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 CountriesWorking Papers from eSocialSciences Abstract: This study employs a two-way fixed effects research design to measure the mortality impact and cost-effectiveness of cancer drugs: it analyzes the correlation across 36 countries between relative mortality from 19 types of cancer in 2015 and the relative number of drugs previously launched in that country to treat that type of cancer, controlling for relative incidence. One additional drug for a cancer site launched during 2006-2010 is estimated to have reduced the number of 2015 disability-adjusted life years (DALYs) lost due to cancer at that site by 5.8%. The estimated cost per life-year gained at all ages in 2015 from cancer drugs launched during 2006-2010 is $1635. The paper estimates that drugs launched during the entire 1982-2010 period reduced the number of cancer DALYs lost in 2015 by about 23%. In the absence of new drug launches during 1982-2010, there would have been 26.3 million additional DALYs lost in 2015. Keywords: eSS; drug; cancer; DALYs; mortality; cost-effectiveness; cancer drug; relative incidence. (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:ess:wpaper:id:12757 Access Statistics for this paper More papers in Working Papers from eSocialSciences |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.